Los Angeles Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Los Angeles Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Buy	+32,999	New	+$1.09M	﹤0.01%	716

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Los Angeles Capital Management's NAMS Position: Q2 2026 in Review

Los Angeles Capital Management opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 32,999 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #716 among its holdings.

194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Los Angeles Capital Management held 32,999 shares of NewAmsterdam Pharma worth $1.12M as of Q2 2026.
NewAmsterdam Pharma was a new Los Angeles Capital Management position in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #716 holding.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.